SABCS 2015

Trastuzumab-containing chemotherapy regimens offer superior survival to in HER2-positive early breast cancer.

Evidence-based clinical practice has evolved and the search for how best to blockade the HER2 receptor in HER2+ breast cancer continues.

Neoadjuvant therapy with the antibody-drug conjugate trastuzumab emtansine (T-DM1) offers clinical response rates in breast cancer.

Tumors’ RNA fusion transcripts appear to be a promising biomarker of genomic instability and prognostic factors.

Trastuzumab after adjuvant chemotherapy for HER2-positive early breast cancer is associated with superior long-term disease-free survival.

Gene copy number, methylation and metabolic changes during neoadjuvant chemotherapy predict treatment outcomes.

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

Whole exome sequencing analysis reveals considerable mutational heterogeneity among cells within lobular carcinoma in situ (LCIS) lesions.

Fibroblast growth factor receptor 1 (FGFR1) gene and ligand co-amplification is associated with endocrine resistance in breast cancer cells.